This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma; leukemia	RNA polymerase I (Pol I)	<p>Cell culture and mouse studies suggest inhibitors of Pol I could help treat hematological cancers. In a panel of cancer cells derived from human hematological malignancies expressing wild-type p53, the small molecule Pol I inhibitor CX-5461 induced apoptotic cell death. In mice transplanted with lymphoma cells expressing wild-type p53, CX-5461 decreased tumor burden in lymph nodes compared with vehicle. Next steps include testing CX-5461 in an Australian Phase I trial to treat hematological cancers in 2H12.</p> <p>Cylene Pharmaceuticals Inc. is developing CX-5461.</p> <p>SciBX 5(30); doi:10.1038/scibx.2012.784 Published online Aug. 2, 2012</p>	Patented by Cylene Pharmaceuticals; available for licensing	<p>Bywater, M.J. <i>et al. Cancer Cell</i>; published online July 10, 2012; doi:10.1016/j.ccr.2012.05.019</p> <p>Contact: Ross D. Hannan, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia e-mail: ross.hannan@petermac.org</p>